Scholars Central

Editorial Board Member

Manchao Zhang

Senior Research Associate, The Ohio State University, USA

About

As published by the journal they serve.

Manchao Zhang has started working on cancer immunotherapy in the 1990s, received rigorous immunological training from Dr. John E. Coligan at NIAID/NIH, dissected the molecular mechanism of action of the TNF super-family member, Light, for the first time reported that a small molecule natural compound as an orally available Bcl-2 family member inhibitor anticancer drug, identified so far the most potent Grb2 SH2 domain antagonist small molecule inhibitors, validated two dozens of anticancer drug targets. He also served as reviewers for a number of peer-reviewed journals and funding agencies.

Research interests

  • Cancer immunotherapy New signal transduction pathways Novel anticancer drug target and Biomarker validation Anticancer drug development Cancer stem cells.

Journals they serve

The seats these journals name them in.

Articles we hold

Articles in the journals they serve whose byline carries this name.

This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels